Cargando…

Open‐label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin‐naïve Asian patients with type 2 diabetes

INTRODUCTION: The present phase 3, randomized, open‐label study compared the efficacy and safety of basal insulin peglispro with insulin glargine after 26 weeks of treatment when added to oral antihyperglycemic medications in insulin‐naïve Asian patients with type 2 diabetes. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirose, Takahisa, Cai, Zhihong, Yeo, Kwee Poo, Imori, Makoto, Ohwaki, Kenji, Imaoka, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754544/ https://www.ncbi.nlm.nih.gov/pubmed/28371567 http://dx.doi.org/10.1111/jdi.12667

Ejemplares similares

Basal insulin peglispro versus insulin glargine in insulin‐naïve type 2 diabetes: IMAGINE 2 randomized trial
por: Davies, M. J., et al.
Publicado: (2016)

Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials
por: Rosenstock, Julio, et al.
Publicado: (2016)

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
por: Orchard, Trevor J., et al.
Publicado: (2017)

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
por: Bergenstal, R. M., et al.
Publicado: (2016)

Randomized double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4
por: Blevins, T., et al.
Publicado: (2016)

Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8
por: Harris, Cynthia, et al.
Publicado: (2017)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
por: Shafie, Asrul Akmal, et al.
Publicado: (2020)

Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes
por: Shiramoto, Masanari, et al.
Publicado: (2020)

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
por: Hoogwerf, Byron J., et al.
Publicado: (2016)

How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
por: Muñoz-Garach, Araceli, et al.
Publicado: (2016)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: A 26‐week, randomized, controlled, Pan‐Asian, treat‐to‐target trial
por: Onishi, Yukiko, et al.
Publicado: (2013)

Basal insulin therapy: Unmet medical needs in Asia and the new insulin glargine in diabetes treatment
por: Tien, Kai‐Jen, et al.
Publicado: (2019)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
por: Hirose, Takahisa, et al.
Publicado: (2019)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin glargine versus other types of basal insulin–clinical and tumor characteristics in patients with breast carcinoma
por: Besic, Nikola, et al.
Publicado: (2013)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
por: Heise, Tim, et al.
Publicado: (2011)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial
por: Rodbard, H W, et al.
Publicado: (2013)

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes
por: Rodbard, H W, et al.
Publicado: (2014)

A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine
por: Belhekar, Mahesh N., et al.
Publicado: (2015)

Comparison of continuous subcutaneous insulin infusion and insulin glargine-based multiple daily insulin aspart injections with preferential adjustment of basal insulin in patients with type 2 diabetes
por: GAO, GUAN-QI, et al.
Publicado: (2014)

Lilly Insulin Glargine Versus Lantus(®) in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)
por: Pollom, Robyn K., et al.
Publicado: (2019)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes
por: Home, P D, et al.
Publicado: (2015)

DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes
por: Buse, John B., et al.
Publicado: (2009)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe, Shinya, et al.
Publicado: (2011)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau, Ip Tim, et al.
Publicado: (2017)

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes
por: Pohlmeier, Harald, et al.
Publicado: (2017)

A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus
por: Pan, Changyu, et al.
Publicado: (2016)

Abstract 5: Similar hypoglycemia duration with once-weekly insulin icodec versus insulin glargine U100 in insulin naïve or experienced patients with T2D
por: Manjunath, Aparna, et al.
Publicado: (2022)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8ut7bouenti7fftia2htgi8sbu